Figure 7: Signaling pathways inhibited by nimesulide and celecoxib are prevalently activated in primary gastric tumors. A, B) Pathway focused gene signature enrichment analysis in two different gastric tumor profiles GSE15459 (A) & GSE22377 (B) shows the prevalent activation of signaling pathways inhibited by nimesulide and celecoxib across primary gastric tumors. Each row in the heatmap represents the pathway activation scores and column denotes the gastric tumor samples. IRF1 (Interferon-β response), Retinoic acid response (RXR), β catenin (Wnt), Myc and E2F1 pathways. C,D) The expression pattern of the genes down regulated by nimesulide (obtained by analyzing the gene expression profile GSE15308, in gastric cancer transcriptome profiles GSE13911 (C) & GSE 17154 D) reveal their predominant elevated expression in a subset of gastric tumors when compared to normal gastric tissues. E) Over-expression of the IRF target genes IFI27 and IFI44 genes are indicated. E) Transcription factor enrichment analysis using Pscan tool in nimesulide down-regulated genes from GSE15308 profile shows enrichment of IRF1 and RXR regulatory regions in their promoters.